Results 121 to 130 of about 42,544 (264)
HBeAg-induced miR-106b promotes cell growth by targeting the retinoblastoma gene
Scientific Reports, 2017 Chronic HBV infection is a major cause of hepatocellular carcinoma (HCC). The association between hepatitis B “e” antigen (HBeAg) and HCC is well-established by epidemiological studies.
J. Samal, M. Kandpal, P. Vivekanandan
semanticscholar +1 more source
Seroconversion of HBsAg in HBeAg positive and HBeAg negative patients with chronic HBV treated with entecavir: a case series [PDF]
, 2010 We report a case series of three HBeAg positive and five HBeAg negative patients (7 males, mean age 50.6 +/- 14.6 years) with chronic HBV infection experiencing sero-conversion after treatment with entecavir (0.5 mg/day or 1 mg/day), initiated in 2007 ...
M. Gobber +8 more
core
Profiles of HBV DNA, ALT, and HBeAg status after stopping lamivudine in patients with HBeAg seroconversion [PDF]
, 2007 AIM: To determine the virological and biochemical relapse rates in Chinese CHB patients with lamivudine-induced HBeAg seroconversion after stopping lamivudine therapy, and to identify significant viral or biochemical factors predictive of subsequent ...
Fung, JYY +6 more
core +1 more source
Soluble B7‐H6 as a Novel Diagnostic Biomarker for Post‐Hepatitis B Cirrhosis: A Clinical Value Study
Journal of Clinical Laboratory Analysis, Volume 40, Issue 15, August 2026.This study investigates the potential of soluble B7‐H6 (sB7‐H6) as a novel diagnostic biomarker for post‐hepatitis B cirrhosis. The infographic visually presents the following key points: (1) Liver Disease Progression: Chronic hepatitis B (CHB) progresses to liver cirrhosis (LC), with serum sB7‐H6 levels increasing stepwise as the disease advances. (2)
Kaiyong Chen +4 more
wiley +1 more source
Journal of Hepatology, 2016 BACKGROUND & AIMS Peginterferon lambda-1a (lambda) is a Type-III interferon, which, like alfa interferons, has antiviral activity in vitro against hepatitis B virus (HBV) and hepatitis C virus (HCV); however, lambda has a more limited extra-hepatic ...
H. Chan +16 more
semanticscholar +1 more source
Factors predicting retreatment for HBeAg-positive patients. [PDF]
, 2019 Factors predicting retreatment for HBeAg-positive patients.
Tsung-Hui Hu (349887) +5 more
core +1 more source
Artificial Organs, Volume 50, Issue 8, Page 1145-1152, August 2026.ALSS short inter‐treatment interval treatment (patients received two ALSS treatments within 48 h) correlates with improved liver function and 90‐day transplant‐free survival of HBV‐ACLF. This result provides a certain theoretical basis for the timing and time interval of ALSS for HBV‐ACLF, enriches the models and contents of ALSS treatment for HBV‐ACLF,
Jingjie Fu +4 more
wiley +1 more source
The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics
Reviews in Medical Virology, 2016 Although a successful vaccine against HBV has been implemented in 184 countries, eradication of hepatitis B virus (HBV) is still not on the horizon. There are over 240 million chronic carriers of HBV globally.
A. Kramvis
semanticscholar +1 more source
Immunological characteristics of HBeAg-negative HCC patients. [PDF]
, 2014 Immunological characteristics of HBeAg-negative HCC patients.
Meng Fang (473455) +7 more
core +1 more source
Alimentary Pharmacology &Therapeutics, Volume 64, Issue 4, Page 517-526, August 2026.In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi +6 more
wiley +1 more source